Assessment of Serum Lipid Profile in Patients with Hypertension
Keywords:
Essential hypertension, Lipid profileAbstract
Background: Hypertension had a global burden on 26.4% of the adult population in 2000, and projections reveal a rise to 29.2 per cent by 2025. Given its high prevalence and associated risks of progression to cardio-vascular disease (CVD) and stroke, early diagnosis becomes crucial. The present study was undertaken for assessing serum lipid profile in patients with hypertensive patients. Subjects and Methods: A total of 50 patients with confirmed diagnosis of essential hypertension were enrolled. Another set of 50 age and gender matched subjects were taken as healthy controls. Complete demographic and clinical details of all the subjects were obtained. Blood samples were obtained from all the subjects and were sent to laboratory where autoanalyzer were used for assessment of serum lipid profile. All the results were recorded in Microsoft excel sheet and were analyzed by SPSS software. Results: Mean Triglycerides among the patients of the essential hypertension group and control group was 1.36 and 1.15 respectively (p- value < 0.05). Mean total cholesterol levels among the patients of the essential hypertension group and control group was 4.96 and 4.05 respectively (p- value < 0.05). Conclusion: Serum lipid profile is significantly deranged in essential hypertension patients.
Downloads
References
1. Stuhlinger MC. Endothelial dysfunction induced by hyperho mocyst(e)inemia: role of asymmetric dimethylarginine. Circu lation. 2003;108(8):933–938. Available from: https://doi.org/ 10.1161/01.cir.0000085067.55901.89.
2. Fagbamigbe AF, Adebowale AS, Ajayi I. An assessment of the nutritional status of ART receiving HIV-orphaned and vulnerable children in South-West Nigeria. Heliyon. 2019;5(12):02925. Available from: https://dx.doi.org/10.1016/ j.heliyon.2019.e02925.
3. Onitiri AC, Sander M, Boyo AE. Serum lipids and lipoproteins in healthy Africans. Clin Chim Acta. 1977;81(1):57–61. Available from: https://doi.org/10.1016/0009-8981(77)90413- 2.
4. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33(4):652–658. Available from: https://doi.org/10.1097/00005344-199904000-00020.
5. Matsuoka H, Itoh S, Kimoto M, Tamai O, Wada Y, Yasukawa H, et al. Asymmetrical dimethylarginine, an endogenous
nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242–247. Available from: https://doi. org/10.1161/01.hyp.29.1.242.
6. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Arch Intern Med. 1992;152(1):56–64.
7. Knuiman JT, West CE. HDL cholesterol in men from thirteen countries. Lancet. 1981;2(8242):367–368. Available from: https://doi.org/10.1016/s0140-6736(81)90687-5.
8. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase path way in diabetes mellitus: role of asymmetric dimethylargi nine and dimethylarginine dimethylaminohydrolase. Circula tion. 2002;106(8):987–992. Available from: https://doi.org/10. 1161/01.cir.0000027109.14149.67.
9. Palloshi A, Fragasso G, Piatti P, Monti LD, Setola E, Valsecchi G, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise test, and normal coronary arteries. Am J Cardiol. 2004;93(7):930–935. Available from: https://doi.org/10.1016/j.amjcard.2003.12.040.
10. Osuji CU, Omejua EG, Onwubuya EI, Ahaneku GI. Serum lipid profile of newly diagnosed hypertensive patients in nnewi. Int J Hypertens. 2012;2012:710486. Available from: https: //doi.org/10.1155/2012/710486.
11. Choudhury KN, Mainuddin AK, Wahiduzzaman M, Islam SM. Serum lipid profile and its association with hypertension in Bangladesh. Vasc Health Risk Manag. 2014;10:327–332. Available from: https://doi.org/10.2147/vhrm.s61019.
